In vitro enhancement of T-cell receptor-targeted lysis after IL-2 treatment of PBL from HIV-seropositive individuals

Michael A. Kolber, Judith Hurley, Jose N. Moreno, Lisa Cabral

Research output: Contribution to journalArticle

Abstract

Individuals with advanced HIV infection have a greater proportion of T-cells that are activated when compared to uninfected individuals. These activated cells are not able to lyse specific targets. The reason for this dysfunction is not well known. In this study we demonstrate that there are CD8+ T-cells from HIV-seropositive individuals that can be targeted to lyse targets with OKT3 (anti-CD3 antibody) but are unable to lyse targets with WT31 (anti-αβ antibody). Treatment of peripheral blood lymphocytes with IL-2 results in an enhancement of WT31-targeted lysis in 9 of 13 individuals evaluated. These findings demonstrate a differential response, in vitro, of CD8+ T-cells to IL-2 treatment. Future work evaluating clinical responses after IL-2 therapy with recovery of targeted lysis in vitro could provide information on screening of individuals for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalClinical Immunology and Immunopathology
Volume86
Issue number2
DOIs
StatePublished - Feb 1998

Keywords

  • Cytotoxicity
  • Immunodeficiency
  • T-cell antigen receptor
  • T-lymphocytes
  • TCGF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'In vitro enhancement of T-cell receptor-targeted lysis after IL-2 treatment of PBL from HIV-seropositive individuals'. Together they form a unique fingerprint.

  • Cite this